EUROBIO-SCIENTIFIC overview

Eurobio Scientific: EB Development obtains a significant majority of the capital with 88.9% held at the end of the Reopened Offer to continue its development with NextStage AM and IK Partners Paris, 19 December 2024 - 10.30am Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible) and EB Development announce the final outcome of the takeover bid initiated by EB Development (the " Offer "), based on the results published on 18 December by the Autorité des marchés financiers (AMF) at the end...

EUROBIO SCIENTIFIC COMPLETES ACQUISITION OF ENDOPREDICT ® GENOMIC TEST FROM MYRIAD GENETICS Paris, August 2 nd , 2024 –7:30 am Eurobio Scientific (FR0013240934, ALERS), a leading French group in in vitro specialty medical diagnostics and life sciences, announces the finalisation of its agreement with Myriad Genetics to acquire the EndoPredict® genomic test. As part of the agreement announced on 7 May 2024 (see press release below), on 1 August 2024 the Group has completed the acquisition of...

EUROBIO SCIENTIFIC SIGNS AN AGREEMENT TO ACQUIRE GENE EXPRESSION TEST FOR BREAST CANCER ENDOPREDICT® Expansion in the oncology segment Development of Eurobio Scientific proprietary product portfolio Increase of international exposure Paris, 7 th May 2024 – 06:30 pm Eurobio Scientific (FR0013240934, ALERS), (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro specialty medical diagnostics and life sciences, announces the signing on May 7 th , 2024 of an agreement to...

2023 ANNUAL RESULTS Growth in Core Business and strategic deployment Core business 1 revenues up 39% to €130m proprietary products account for 30% of revenues 38% of revenues generated outside France Resilient results within a strategic transformation phase Free cash flow of €26.4m Net financial debt reduced to €5.5m, with €89m cash position Paris, April 10, 2024 - 5.40pm - Eurobio Scientific (FR0013240934, ALERS), a leading French group in in vitro medical diagnostics and life sciences,...

MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2023 Paris, le 30 octobre 2023 – 17h45 Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro de spécialité, annonce avoir mis à disposition du public et déposé auprès de l’Autorité des Marchés Financiers (AMF) le 30 octobre 2023 son rapport financier semestriel au 30 juin 2023. Le rapport financier semestriel peut être consulté sur le site Internet de la société...

Eurobio Scientific: GenDx reduces organ matching time to 3 hours Launch of NGS-Turbo, a unique test to match organs on Oxford Nanopore Technologies sequencing devices A valuable technological partnership with Oxford Nanopore Technologies A significant advance in HLA typing Paris, 17 th October 2023 – 5:40 pm Eurobio Scientific (FR0013240934, ALERS), (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro specialty medical diagnostics and life sciences, today announces the...

ACCELERATION OF STRATEGIC DEPLOYMENT IN THE FIRST HALF OF 2023 Strong growth in half-year core business revenues, up 37% Successful deployment of the Group's strategy: Share of proprietary products up, at 30% of revenues Continued internationalization, with 35% of revenues now generated outside of France Acquisition of DID in Italy effective as of July 1 st , 2023 Paris, July 2 4 , 2023 – 5: 45 pm Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro...

2022 ANNUAL RESULT S Very strong performance and strengthening of the Core Business Core Business 1 revenue s up 15% to €93. 5 M (+53% since 2019) Increase in the share of proprietary products at 18% of revenue s International sales at 25% of revenue s After two exceptional years, decline in COVID business at 27% of revenue s in the second half, in line with expectations Margins maintained at high levels with EBITDA at €40. 5 M or 26.5% of revenue s Excellent cash generation capacity at €...